Clinical Trial Update: Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial assessing anti-Xa activity of enoxaparin for preventing venous thromboembolism in severe nephrotic syndrome; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrotic Syndrome

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Military Institute od Medicine National Research Institute | Conditions: Nephrotic Syndrome | Phase 2, Phase 3 | Status: TERMINATED